|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM366045695 |
| 003 |
DE-627 |
| 005 |
20250305141506.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231227s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202309591
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1219.xml
|
| 035 |
|
|
|a (DE-627)NLM366045695
|
| 035 |
|
|
|a (NLM)38113900
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Hui
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel-Mediated Reprogramming of Cancer-Associated Fibroblasts in Osteosarcoma
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.04.2024
|
| 500 |
|
|
|a Date Revised 08.05.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a In osteosarcoma, immunotherapy often faces hurdles posed by cancer-associated fibroblasts (CAFs) that secrete dense extracellular matrix components and cytokines. Directly removing CAFs may prove ineffective and even promote tumor metastasis. To address this challenge, a sequential nanocomposite hydrogel that reshapes CAF behavior is developed, enhancing tumor-infiltrating T-cells in osteosarcoma. The approach utilizes an injectable blend of carboxymethyl chitosan and tetrabasic polyethylene glycol, forming a hydrogel for controlled release of a potent CAF suppressor (Nox4 inhibitor, Nox4i) and liposomal Doxorubicin (L-Dox) to induce immunogenic cell death (ICD) upon in situ administration. Nox4i effectively counters CAF activation, overcoming T-cell exclusion mechanisms, followed by programmed L-Dox release for ICD induction in stroma-rich osteosarcoma models. Combining the co-delivery gel with αPD-1 checkpoint inhibitor further enhances its effectiveness in an orthotopic osteosarcoma model. Immunophenotyping data underscore a significant boost in tumor T-cell infiltration and favorable anti-tumor immunity at the whole-animal level
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Nox4 inhibition
|
| 650 |
|
4 |
|a cancer‐associated fibroblasts
|
| 650 |
|
4 |
|a chemoimmunotherapy
|
| 650 |
|
4 |
|a osteosarcoma
|
| 650 |
|
4 |
|a sequential nanocomposite hydrogels
|
| 650 |
|
7 |
|a Nanogels
|2 NLM
|
| 650 |
|
7 |
|a liposomal doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a Hydrogels
|2 NLM
|
| 650 |
|
7 |
|a Polyethylene Glycols
|2 NLM
|
| 650 |
|
7 |
|a 3WJQ0SDW1A
|2 NLM
|
| 700 |
1 |
|
|a Chen, Yu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wei, Ran
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Jinlong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Jiahui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Wenbin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Zhenfei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wupur, Zulpikar
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Yujing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Meng, Huan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 15 vom: 08. Apr., Seite e2309591
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:15
|g day:08
|g month:04
|g pages:e2309591
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202309591
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 15
|b 08
|c 04
|h e2309591
|